PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32642151-0	2020	Combination of apatinib and docetaxel in treating advanced non-squamous non-small cell lung cancer patients with wild-type EGFR: a multi-center, phase II trial.	apatinib	15-23	epidermal growth factor receptor	Homo sapiens	123-127	
32642151-1	2020	Background: This trial aimed to investigate the treatment response, survival profiles and treatment-related adverse events (AEs) of apatinib plus docetaxel in advanced non-squamous non-small cell lung cancer (NSCLC) patients with wild-type epidermal growth factor receptor (EGFR).	apatinib	132-140	epidermal growth factor receptor	Homo sapiens	240-272	
32642151-11	2020	Conclusions: Apatinib plus docetaxel is an effective and tolerable treatment option for advanced non-squamous NSCLC with wild-type EGFR.	apatinib	13-21	epidermal growth factor receptor	Homo sapiens	131-135